KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Operating Leases: 2021-2024

Historic Operating Leases for Castle Biosciences (CSTL) over the last 4 years, with Dec 2024 value amounting to $14.3 million.

  • Castle Biosciences' Operating Leases rose 72.23% to $25.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.3 million, marking a year-over-year increase of 72.23%. This contributed to the annual value of $14.3 million for FY2024, which is 1.21% up from last year.
  • As of FY2024, Castle Biosciences' Operating Leases stood at $14.3 million, which was up 1.21% from $14.2 million recorded in FY2023.
  • Over the past 5 years, Castle Biosciences' Operating Leases peaked at $14.3 million during FY2024, and registered a low of $6.9 million during FY2021.
  • In the last 3 years, Castle Biosciences' Operating Leases had a median value of $14.2 million in 2023 and averaged $13.4 million.
  • Data for Castle Biosciences' Operating Leases shows a peak YoY soared of 67.14% (in 2022) over the last 5 years.
  • Castle Biosciences' Operating Leases (Yearly) stood at $6.9 million in 2021, then surged by 67.14% to $11.5 million in 2022, then rose by 22.89% to $14.2 million in 2023, then rose by 1.21% to $14.3 million in 2024.